Recently, FGFR::TACC fusions have been reported in a variety of non-epithelial cancers, including FGFR1::TACC1 fusions as a novel alternative genetic driver in rhabdomyosarcoma [30], and FGFR2::TACC2 fusions as a mechanism of multidrug resistance in TKI-treated gastrointestinal stromal tumors (GIST) [31]. The gene discussed is TACC2; the disease is rhabdomyosarcoma.